“Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase”, J of Skin, vol. 5, no. 1, p. s29, Jan. 2021, doi: 10.25251/skin.5.supp.29.